KPV: The Complete Guide
Three amino acids derived from the C-terminal end of alpha-melanocyte-stimulating hormone, studied for inhibiting NF-κB without binding melanocortin receptors.
What is KPV?
Think of KPV as a three-letter fragment snipped from the tail of a longer, well-studied hormone. The longer hormone is called alpha-melanocyte-stimulating hormone, or α-MSH for short. It's a 13-amino-acid chain your body produces, and it has well-documented anti-inflammatory effects.
Researchers noticed something unusual about α-MSH: when they cut off just the last three amino acids — lysine, proline, and valine — that tiny fragment still seemed to carry most of the anti-inflammatory effect of the full hormone. Those three amino acids together are called KPV. Three letters, one for each amino acid.
In peptide research, this is the equivalent of finding out that the active ingredient in a 13-ingredient recipe was really just three of the ingredients all along. The bigger molecule isn't doing the work — the tail end is.
What makes KPV interesting beyond its size is what it doesn't do. Other fragments of α-MSH can cause skin pigmentation as a side effect, because they bind to receptors involved in melanin production. KPV doesn't have the part of the sequence needed for that binding. So research suggests it delivers anti-inflammatory effects without the pigmentation that comes with related compounds like Melanotan II or PT-141.
It also works through a different door. Most anti-inflammatory peptides act on receptors sitting on the outside of cells. KPV is small enough to be carried inside cells through a transporter called PepT1 — and PepT1 happens to be more active in inflamed tissue than healthy tissue. So the more inflamed a tissue is, the more KPV it pulls in. It's a self-targeting design that researchers find unusual.
Research Applications
Research on KPV spans inflammation pathways, intestinal targeting, skin renewal, and antimicrobial activity — a broad profile for a three-amino-acid peptide.
Research suggests KPV switches off NF-κB, the "master switch" that tells cells to produce inflammatory signals. Most anti-inflammatory drugs work downstream — they catch the signals after they’ve been sent. KPV appears to act at the source, before the alarm goes out.
KPV enters cells through a transporter called PepT1. Healthy colon tissue barely uses PepT1, but inflamed colon tissue ramps it up. The more inflamed the tissue, the more KPV it absorbs. The peptide effectively concentrates itself where it’s most needed.
Research suggests KPV encourages skin renewal and wound healing by activating tissue remodelling genes. It’s studied in both cosmetic research and in chronic skin wound applications.
Beyond anti-inflammatory effects, research has shown KPV directly attacks bacteria like Staphylococcus. It disrupts the bacterial cell membrane on contact — a separate mechanism from how it handles inflammation. Two jobs, one tripeptide.
KPV comes from α-MSH but lacks the part of the sequence that binds melanin receptors. Research suggests it carries the anti-inflammatory effect of its parent molecule without the pigmentation effect that other α-MSH derivatives cause.
Lysine-Proline-Valine. One of the smallest bioactive peptides ever identified, yet research suggests it carries the anti-inflammatory power of its 13-amino-acid parent.
How KPV Works
NF-κB inhibition: Cells are constantly listening for danger signals — things like the cytokine IL-1β that tell them "something's wrong, start the inflammatory response." When those signals arrive, a pathway called NF-κB switches on, and the cell starts producing more inflammatory proteins. Research suggests KPV throws a wedge into that process. Specifically, it stops a protein called IκB-α from being broken down, which means NF-κB stays trapped inside the cell instead of moving into the nucleus to switch on inflammatory genes. The result, in plain terms: the inflammatory alarm gets muffled at the source.
PepT1 transport: This is the part that makes KPV unusual among anti-inflammatory peptides. PepT1 is a transporter that normally exists in the small intestine, where it absorbs small bits of dietary protein. It barely shows up in healthy colon tissue. But during inflammatory bowel disease, the inflamed parts of the colon ramp up PepT1 production. KPV is small enough — just three amino acids — to be carried through PepT1 like a dietary fragment. So inflamed colon tissue pulls in more KPV than healthy colon tissue does. The peptide concentrates itself at the site of inflammation without needing any external targeting.
Non-MCR mechanism: When researchers first investigated KPV, the assumption was that it would work the same way α-MSH does — by binding melanocortin receptors (MCRs), the receptors involved in α-MSH's effects. That assumption turned out to be wrong. KPV doesn't have the part of the sequence needed for MCR binding. It works through a completely different pathway: PepT1 uptake combined with NF-κB inhibition inside the cell. Research has confirmed the effect is real but the mechanism isn't what was originally expected.
Antimicrobial action: Separately from its anti-inflammatory work, research suggests KPV can directly damage bacterial cell membranes. It depolarises and permeabilises the membranes of bacteria like Staphylococcus, killing the cell at very low concentrations. This activity holds up under physiological salt conditions, which matters because many antimicrobial peptides lose effectiveness in real biological environments. Two distinct jobs — calming inflammation, killing bacteria — running through one three-amino-acid molecule.
Storage Guidelines
Store at 2–8°C in a cool, dry place. Protect from light and moisture. Refrigerate once in solution form.
Frequently Asked Questions
Technical Specifications
Compiled by the Southern Pacific Labs research team. Last updated April 2026.
Published References
- Dalmasso G, Charrier-Hisamuddin L, Nguyen HT, et al. “PepT1-mediated tripeptide KPV uptake reduces intestinal inflammation.” Gastroenterology, 2008. PubMed
- Xiao B, Xu Z, Viennois E, et al. “Orally Targeted Delivery of Tripeptide KPV via Hyaluronic Acid-Functionalized Nanoparticles Efficiently Alleviates Ulcerative Colitis.” Molecular therapy : the journal of the American Society of Gene Therapy, 2017. PubMed
- Pawar K, Kolli CS, Rangari VK, et al. “Transdermal Iontophoretic Delivery of Lysine-Proline-Valine (KPV) Peptide Across Microporated Human Skin.” Journal of pharmaceutical sciences, 2017. PubMed
- Luger TA, Brzoska T. “alpha-MSH related peptides: a new class of anti-inflammatory and immunomodulating drugs.” Annals of the rheumatic diseases, 2007. PubMed
Browse all KPV research on PubMed →
Related Research Guides
More in Recovery & Tissue Repair
Repair-focused gut peptide — complementary to KPV via VEGFR2 and nitric oxide pathways for inflammation-plus-repair research.
Read guide →MelanocortinAnother α-MSH derivative — but this one binds melanocortin receptors directly, a fundamentally different pathway from KPV.
Read guide →RecoveryTissue repair via actin regulation and cell migration — a complementary regenerative mechanism studied alongside KPV in recovery protocols.
Read guide →